The benefit of early survival on PD versus HD—Why this is (still) very important

Mark R Marshall¹,²,³

Abstract
There are a number of misconceptions around the identified early survival benefit of peritoneal dialysis (PD) relative to hemodialysis (HD), including that such benefits “even out in the end” since the relative risk of death over time eventually encompasses 1.0 (or even an estimate that is unfavorable to PD); that the early benefit is, in fact, most likely due to unmeasured confounding; and such benefits are only due to the influence of central venous catheters and “crash starters” in the HD group. In fact, the early survival benefit results in a substantial gain of patient life years in PD cohorts relative to HD ones, even if it the benefit appears to “even out in the end,” is relatively insensitive to unmeasured confounding, and persists even when the effects of central venous catheters are accounted for. In this review, the calculations and arguments are made to support these tenets. Survival on dialysis is still one of the most important considerations for all stakeholders in the end-stage kidney disease community, including patients who rank it among their top priorities. Shared decision-making is a fundamental patient right and requires both balanced information and an iterative mechanism for a consensual decision based on shared understanding and purpose. A cornerstone of this process should be an explicit discussion of the early survival benefit of PD relative to HD.

Keywords
Epidemiology, hazard ratio, mortality, predialysis education, shared modality decision-making

Introduction
The comparatively better survival of peritoneal dialysis (PD) patients relative to hemodialysis (HD) patients in the first year of dialysis was first described 40 years ago.¹ This early survival benefit has also been evident in the majority of studies in the more modern era, as will be shown below. The nature of this benefit, however, is widely misunderstood by stakeholders in the dialysis community. The main misconceptions include that such benefits “even out in the end” with no net gain in survival since the relative risk of death over time eventually encompasses 1.0 (or even an estimate that is unfavorable to PD); that the early benefit is, in fact, most likely due to unmeasured confounding; and such benefits are only due to the influence of central venous catheters and “crash starters” in the HD group. These tenets are, in the main, incorrect. In this narrative, I will address these issues and suggest clinical implications for care, based on the general position that the relationship between modality and early survival is both real and likely to be causal.

Why early, beneficial hazard ratios do not “even out in the end” if the hazard ratio subsequently encompasses 1.0
In medical research, comparing the relative risk of death between two treatments involves the calculation of a ratio: a rate ratio, an odds ratio, or a hazard ratio (HR) depending on the type of statistical test used for the computation. A Poisson model compares the frequency (rate ratio), a

¹ Department of Renal Medicine, Counties Manukau District Health Board, Auckland, New Zealand
² School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
³ Medical Affairs, Baxter Healthcare (Asia) Pte Ltd, Singapore

Corresponding author:
Mark R Marshall, Department of Renal Medicine, Counties Manukau District Health Board; School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Medical Affairs, Baxter Healthcare (Asia) Pte Ltd, Singapore.
Email: markrogermarshall@icloud.com
logistic model the odds (odds ratio), and a Cox model the hazard (HR) of the event of interest, here being death. All of these ratios are roughly comparable when they are used for large samples and when the outcome is common (e.g. death in dialysis populations). By far, the most common method used for comparing the risk of death in epidemiological research is the Cox model. For all practical purposes, the “hazards” calculated by the Cox model can be thought of as incidence rates, and thus, the HR can be roughly interpreted as the incidence rate ratio.2

So, as we all should know, an HR for of 1.2 for death between treatment A and treatment B at time $T$ indicates the following: there are 20% more deaths on treatment A and treatment B in those followed up to time $T$. However, this interpretation assumes that the HR is constant over time (“proportional hazards”). In reality, the HR at time $T$ ignores the distribution of events before (and obviously after) time $T$, and should be regarded as an “instant” ratio through to and calculated at the time of follow-up.2 If the HR has not been constant at each point up until time $T$, then the HR at that time is certainly not interpretable as an “average” effect over the period of observation, and at best can be regarded as a smoothed estimate.

Using an example quoted in a seminal article by Hernán et al.,2 consider the Women’s Health Initiative, a randomized clinical trial that compared the risk of coronary heart disease of women allocated to combine hormone therapy versus placebo.3 This mean follow-up time in the study was 5.2 years. The primary result from the trial was expressed as the HR for coronary artery disease—“Combined hormone therapy was associated with a hazard ratio of 1.24.” However, the HRs varied markedly depending on duration of follow-up: 1.81, 1.34, 1.27, 1.25, 1.45, and 0.70 for follow-up to years 1, 2, 3, 4, 5, and 6 or more, respectively. The 24% increase in the rate of coronary heart disease that many consider as the definitive effect of combined hormone therapy arises from the decision of investigators to define follow-up as being 5.2 years. As pointed out by Hernán in his paper, a trial with a shorter follow-up would have reported an 80% increase, whereas a longer trial would have reported little or no increase at all.4

How then should we should then interpret time-varying HRs, if they appear to “even out” in the end? Consider another example, namely the survival of general populations in Liberia and the United States. The survival of these populations is well defined in life tables from the World Health Organization (https://www.who.int/gho/mortality_burden_disease/life_tables/life_tables/en/). As shown in Figure 1, the rate of death in Liberia is 11.1-fold higher than that in the United States during childhood but is only marginally higher at complete follow-up. There is, therefore, an early survival benefit in the United States, although mortality risk appears to mostly “even out” by the end of follow-up. The reason for this, of course, is that most people are now dead in both countries. At any one point in time, however, many more patients are alive in the United States compared to Liberia. The early survival benefit in the United States means that more patients live longer in that country, despite the apparent “evening out” at long-term follow-up.

This interpretation also applies to the comparison of PD versus HD. As an example, consider a hypothetical scenario of 1000 patients starting PD and 1000 identical ones starting HD, as modeled in Figure 2 (see Stata code in Online Supplementary Material). In this example, the annual mortality is set at an unrealistically high rate for the purposes of illustration, and there is no dropout or loss to follow-up. The mortality risk with PD has been simulated such that it is lower than that with HD initially, but higher later on. Note, however, that HR for death on PD versus HD over the entire period is equal to 1.00 (95% confidence intervals (CIs) 0.91, 1.10). However, despite the equal hazards at 5 years, the typical longevity of PD patients is 2.35 years, as opposed to 1.83 years for those on HD. A greater number of patients in the cohort benefit from the early survival advantage of PD, and a lower number are harmed by the late survival
disadvantage. The net effect is patient life years saved with PD compared to HD, despite the relative risk of death that appears to “even out” in the end.

Finally, let us examine a real-world example, using the study by Kumar et al.5 This study is notable for several reasons. First, it can be regarded as one of the most methodologically rigorous analyses comparing mortality risk with PD versus HD and used a methodology that computes a cumulative HR, not (as is usual) the “instant” HR. Second, it makes adjustments for not only typical demographic and clinical confounders but also neighborhood family income and neighborhood education level. Third, the study demonstrates convergent validity using both “intention to treat (ITT)” and “as treated (AT)” frameworks.6 Finally, the sampling frame excluded any HD who initiated dialysis urgently with a catheter in an effort to reduce case-mix bias. In this study, the cumulative survival favors PD over HD for the first 2–3 years, with little in the way of significant difference in adjusted survival thereafter (Figure 3). In Table 1, the marginal gain in life years for the PD cohort relative to the HD cohort is presented when follow-up of this cohort is restricted to 1, 2, 3, 4, and finally, 5 years. As can be seen, in the AT analysis, the average life expectancy of a PD patient is approximately 0.14 years longer at the 5-year landmark than that of a corresponding HD patient. Once again, despite the survival probabilities appearing to “even out” in the end, there is a net gain in patient life years saved from the early survival benefit on PD in this study.

In short, there is a disconnect between typical survival time and the HR from conventional Cox models when comparing PD versus HD because of the time-varying HR. The single number that is generated from such models over the entire period of observation does not provide an accurate reflection of an “average” effect. Should such a number be required, a valid estimate can be generated using more complicated (and seldom performed) computations, for instance, discrete-time hazard models or cumulative HRs, as developed by Vonesh, and used in a number of papers (including Kumar et al. above) that generate adjusted population-averaged survival curves.5,9,10 In the literature at large, however, the majority of computations report standard HRs using conventional Cox models. These estimates must be interpreted correctly.

Why early benefit from PD versus HD is unlikely to be explained in entirety by unmeasured confounding

When discussing the early survival benefit of PD versus HD, the question of causality always arises. Is this effect of modality on mortality an actual one or merely an association that is apparent because we cannot adjust for all important confounders? This is a key question. Under what must be currently considered a strong assumption of causality, there are potentially hundreds of thousands of life-years to be gained from greater exposure to a lower death rate early after dialysis inception, given the millions of dialysis patients on the planet today. It behooves us to understand if this is a real opportunity or not.

In assessing whether this early survival benefit may be an artifact of residual confounding, there are two approaches to be taken. The first is to triangulate finding with those in randomized controlled trials (RCTs). Of course, it should be remembered that RCTs are not always a better reflection of reality that observational studies, despite their well-accepted higher ranking in the evidence hierarchy.11 Randomized clinical trials are known to
systematically underrepresent older, frailer, and less well-educated patients, who are often not considered for participation. The results of RCTs are therefore often difficult to generalize to unselected populations. Such is the case with the largest trial ever performed in dialysis patients, yielding an unreasonably young and healthy patient sample, with results that are of questionable relevance to the “real world.” Notwithstanding, clinical trials are a useful tool with which to assess causality (can the intervention work), before such steps are taken to show clinical effectiveness (does it work).

The second approach is to estimate the extent to which bias due to unmeasured confounding may have over- or underestimated the true effect. In this technique, the prevalence of a hypothetical unmeasured confounder is varied among patients in the reference and comparator groups as well as the strength of association between the hypothetical unmeasured confounder and the outcome of interest (here being mortality risk). The models are created to reflect plausible scenarios in which unmeasured confounding might be at play. The resulting impact on the baseline relative risk ratio (RR) can be computed in a number of ways but is most easily modeled using bias formulas. Such modeling shows what sort of unmeasured confounder is necessary to abrogate the association of interest, in terms of both the distribution of the confounder between groups and its strength of association with the outcome (e.g. see literature). If such an unmeasured confounder may plausibly exist, then the association of interest is deemed sensitive to unmeasured confounding. If not, then the measured association can be considered as being closer to a causal one.

So, using these two approaches, how robust is the tenet of an early survival benefit of PD versus HD? As a first step, it is appropriate to quantify the extent of this benefit from cumulative clinical experience. There is no adequate synthesis of evidence in the literature, although an attempt is planned. It is difficult to meta-analyze studies comparing PD and HD due to the heterogeneity of data, differences and deficiencies concerning various computations within articles, and often variable and patchy reporting. To provide some substance for further discussion, however, an informal meta-analysis of the literature is presented below.

In this analysis, the following studies were included:

- Only studies published from 1997, to exclude studies based on obsolete practices.
- Only studies published up to 18 October 2018, when the literature search was completed.
- Excluding combination dialysis, where PD is augmented by one to two sessions of HD per week.
- Where possible, including publications that excluded deaths up to 90 days (eliminating the interim or short-term HD patients who have very high mortality due to factors independent of dialysis modality).

Table 1. Marginal, covariate adjusted survival estimates from Kumar et al. in “as-treated” (AT) and “intention-to-treat” (ITT) analyses, respectively, and their difference (absolute risk reduction) and RMST through 5 years and the corresponding life years gained (differences in RMST) through the first 5 years, between PD and HD cohorts (courtesy of Edward F Vonesh and Victoria A Kumar, personal communication, 27 June 2019).

| Time (years) | Survival PD | Survival HD | Absolute risk reduction | RMST PD | RMST HD | Life years gained for PD |
|-------------|-------------|-------------|-------------------------|---------|---------|-------------------------|
| 1           | 0.94914     | 0.88563     | 0.063512                | 0.97425 | 0.93104 | 0.04321                 |
| 2           | 0.87383     | 0.83253     | 0.041298                | 1.88791 | 1.78649 | 0.10142                 |
| 3           | 0.81424     | 0.77523     | 0.039008                | 2.74275 | 2.5962  | 0.14655                 |
| 4           | 0.72404     | 0.73394     | 0.009903                | 3.45044 | 3.34455 | 0.10589                 |
| 5           | 0.6759      | 0.69243     | 0.016532                | 4.11727 | 4.05955 | 0.05772                 |
The initial pooled data include patients from 38 countries, and >150,000 PD and >1 million HD patients, and were analyzed in such a way to determine “instant” relative RR up to the landmarks of 6 months, 1 year, and 2 years after dialysis inception.\(^5,10,34,35\) The remaining study has no particular explanation, although it is interesting to note the higher use of diuretics in HD patients than PD patients, allowing speculation that residual renal volume (but not necessarily function) might be unusually high in the HD group, contrary to customary findings in the literature.\(^73\)

The final pooled data for the meta-analysis included 811,319 patients from 18 countries. Extraction of data measurements was performed in adherence of standard operating procedures in the Cochrane Handbook for Interventions in Systematic Reviews (https://training.cochrane.org/handbook), and results were expressed as relative RR with 95% confidence intervals (CIs).\(^77\) Data were meta-analyzed with RevMan version 5.3 using random-effects models. For RCTs, the Mantel–Haenszel relative RR was computed from reported numbers of deaths. For observational studies, the DerSimonian and Laird inverse variance method was used to calculated relative RRs from natural logarithms of adjusted odd ratios or HRs (and their standard errors).\(^78\) The details of the meta-analysis are shown in Figure 4 and summarized in Figure 5. Overall, there is a notable survival benefit in the first year of dialysis in these studies, which often extends up to 2 or more years.

As can be seen, there is a high degree of heterogeneity in these analyses. This is not only related to the different sampling frames and eras of studies, but also from variations in how they handle data. First, some studies use the ITT framework for analysis and others the AT framework. These frameworks provide different insights and often disparate statistical estimates.\(^6,37\) Both have their drawbacks. In general, ITT models tend to underestimate differences in risk between groups due to progressive contamination that occurs over time that is ignored. On the other hand, AT models can overestimate differences in risk between groups, due to switching of patients that is accounted for, but often without including changes in patient health status that also occur concomitantly along the way. The impact of these different frameworks can be readily appreciated from the forest plots. The second methodological source of heterogeneity is variation around how HRs are calculated in the studies. All give relative RRs at landmarks of 6 months, 1 year, and 2 years postdialysis inception. However, some articles calculate these as instantaneous HRs,\(^34,39,47,51,58-60,64,79\) while some calculate a genuinely cumulative estimates,\(^8,80\) and yet others have interval-specific estimates computed over anywhere between 342,53 and 12 month intervals. These two sources of variation result in an inevitable degree of heterogeneity within the meta-analysis, that cannot be ameliorated in any way.

Notwithstanding these difficulties, a robust observation can be made of a significant early survival benefit with PD versus HD. The question then arises: Is this effect due to unmeasured confounding? At a minimum, these studies all adjusted for differences in patient’s age, gender, diabetic status, and race between groups. At a maximum, they also accounted for detailed comorbidity, center effect, era, and socioeconomic and marital status. However, none of the studies could possibly have included all factors that are important to patient outcomes. For instance, unmeasured differences in adherence and functionality might be present between groups and contributing to the observed...
Figure 4. Forest plots from the meta-analysis of cohort studies comparing risk of death in those treated with HD versus PD, summarized for landmarks of 6 months (top panel), 1 year (middle panel), and 2 years follow-up (lower panel), subgrouped according to the intention-to-treat and as-treated analytical frameworks.

PD: peritoneal dialysis; HD: hemodialysis.
differences in outcomes. How can we assess the causal veracity of the early survival benefit?

As described above, the first approach is to use RCTs. There have been two RCTs of PD and HD in the modern era, and one in an older era which is invalidated by obsolete practices.81 The most recent of the modern ones is still to be published in full, but has been presented at the Annual Scientific Meeting of the American Society of Nephrology in the High Impact Clinical Trials session, and is published as a peer-reviewed abstract (ChinaQ: trial registration NCT01413074 at clinicaltrials.gov).82 The single fully reported RCT in the modern era is the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) study.83 No other trials have been identified in systematic reviews.84 In the ChinaQ study, 668 patients from 21 centers in China were randomized to either PD or HD with a weighted mean patient follow-up of 39.1 weeks. In the NECOSAD study, 38 patients were randomized, with an overall weighted mean patient follow-up of 2.23 years. Combining the results of both these trials, the weighted mean relative RR for death on PD versus HD is 0.61 (95% CI 0.36, 1.06) at a weight mean follow-up time of 43.2 weeks (see forest plot in Figure 6). While this is statistically nonsignificant as a result of imprecision, it is nonetheless directionally consistent with those of the meta-analysis reported above.

The second approach uses a sensitivity analysis and can be performed using bias formulas.20–24 Table 2 presents various scenarios around a hypothetical unmeasured confounder and the resulting impact on the baseline relative RR. These are shown for the landmarks of 3 months, 1 year, and 2 years. The rows show a different prevalence of the unmeasured confounder in each group, and the columns show a different strength of association between the unmeasured confounder and death. When the unmeasured confounder is introduced into the models, the relative risks identified in the meta-analysis are only sensitive to an implausibly strong and/or implausibly unbalanced confounder. For example, to account for the association at 6 months, the unmeasured confounder would have been needed to be three to four times more prevalent in patients in one group than the other and would have been needed to have a relative risk for mortality of around 10. The effect identified in the meta-analysis is otherwise insensitive and persistent after adjustment for other degrees of confounding. A similar situation exists at the 12-month landmark but not the 24-month landmark. For completeness, it should be acknowledged that these conclusions are subject to several strong assumptions—these bias formulas work best with rare events, and when the effect-size of the unmeasured confounder is small.24,85 In general, however, the technique shows acceptable approximations even if the events are not rare, and bias is only slight as the effect-size of the unmeasured confounder increases24.

Given the consistency of the observational data, the directional corroboration of experimental data, the modest sensitivity of estimates to unmeasured confounding, one can make a strong case for the veracity of the association between modality and early survival benefit, and a reasonable case for a substantial element of causality in the relationship.

**Why this early survival benefit is not likely to be from central venous catheter use alone (and why this is not a “deal-breaker” anyway)**

If the relationship between modality and early survival benefit has a substantial element of causality, what is the said cause? There are three main hypotheses:

- Better preservation of residual kidney function (RKF) with PD compared to HD. RKF decreases the relative risk of death in both PD86 and HD.87 Moist

| Study or Subgroup | Events | Total | Events | Total | Weight | M-H | Risk Ratio Random, 95% CI | Year | M-H | Random, 95% CI |
|-------------------|--------|-------|--------|-------|--------|-----|---------------------------|------|-----|----------------|
| Korevaar (Netherlands, 2003) | 5      | 20    | 9      | 18    | 37.5%  | 0.50| [0.21, 1.22] | 2003 | 0.69| [0.35, 1.18] |
| Yu (China, 2018) | 13     | 332   | 19     | 336   | 62.5%  | 0.69| [0.35, 1.18] | 2018 | 0.69| [0.35, 1.18] |
| Total (95% CI)      | 352    | 354   | 100.0% | 100.0%| 0.61  | [0.36, 1.06]|
| Total events        | 18     | 28    |        |       |        |     | 0.01 | 0.1 | 1   | 10  | 100 |

Heterogeneity: Tau² = 0.00; Chi² = 0.33, df = 1 (P = 0.57); I² = 0%

Test for overall effect: Z = 1.76 (P = 0.08)

Figure 6. Forest plot of mortality risk from the two randomized controlled trials in the modern era.
et al. showed that PD had a 65% lower risk of loss of RKF compared to HD during first year of dialysis in incident end-stage kidney disease (ESKD) patients. Wang et al. reported a 50% reduction in all-cause mortality and cardiovascular death in PD patients for every 1 ml/min increase in residual glomerular filtration rate.

- Morbidity and mortality associated with central venous catheter (CVC) use. Around the world, patients most often initiate HD using a CVC. At the most recent reporting, this figure was 80% in the United States. Studies have clearly documented that the use of CVCs is associated with increased mortality compared to the use of

### Table 2. Sensitivity of relative risks (expressed as point estimates only) for the association between PD and early mortality benefit from Figure 3, after adjustment for various scenarios of a hypothetical unmeasured confounder.

| Proportion with unmeasured confounder in each group (n) | 6 month landmark | Relative risk of death associated with the unmeasured confounder (RR\textsubscript{UC}) |
|------------------------------------------------------|------------------|-------------------------------------------------------------------------------------|
| PD group | HD group | RR\textsubscript{UC} = 0.9 | RR\textsubscript{UC} = 0.7 | RR\textsubscript{UC} = 0.5 | RR\textsubscript{UC} = 0.3 | RR\textsubscript{UC} = 0.1 |
| 0.65   | 0.2     | 0.59 | 0.65 | 0.75 | 0.88 | 1.11 |
| 0.6    | 0.25    | 0.58 | 0.63 | 0.70 | 0.80 | 0.94 |
| 0.55   | 0.3     | 0.57 | 0.61 | 0.66 | 0.72 | 0.81 |
| 0.5    | 0.35    | 0.57 | 0.59 | 0.62 | 0.65 | 0.70 |
| 0.45   | 0.4     | 0.56 | 0.57 | 0.58 | 0.59 | 0.60 |
| 0.4    | 0.45    | 0.56 | 0.55 | 0.54 | 0.53 | 0.52 |
| 0.35   | 0.5     | 0.55 | 0.53 | 0.51 | 0.48 | 0.45 |
| 0.3    | 0.55    | 0.55 | 0.51 | 0.48 | 0.44 | 0.39 |
| 0.25   | 0.6     | 0.54 | 0.50 | 0.45 | 0.39 | 0.33 |
| 0.2    | 0.65    | 0.53 | 0.48 | 0.42 | 0.35 | 0.28 |

| Proportion with unmeasured confounder in each group (n) | 12 month landmark | Relative risk of death associated with the unmeasured confounder (RR\textsubscript{UC}) |
|------------------------------------------------------|------------------|-------------------------------------------------------------------------------------|
| PD group | HD group | RR\textsubscript{UC} = 0.9 | RR\textsubscript{UC} = 0.7 | RR\textsubscript{UC} = 0.5 | RR\textsubscript{UC} = 0.3 | RR\textsubscript{UC} = 0.1 |
| 0.65   | 0.2     | 0.87 | 0.97 | 1.11 | 1.31 | 1.64 |
| 0.6    | 0.25    | 0.86 | 0.94 | 1.04 | 1.18 | 1.40 |
| 0.55   | 0.3     | 0.85 | 0.90 | 0.97 | 1.07 | 1.20 |
| 0.5    | 0.35    | 0.84 | 0.87 | 0.91 | 0.96 | 1.03 |
| 0.45   | 0.4     | 0.83 | 0.84 | 0.86 | 0.87 | 0.89 |
| 0.4    | 0.45    | 0.83 | 0.82 | 0.80 | 0.79 | 0.77 |
| 0.35   | 0.5     | 0.82 | 0.79 | 0.75 | 0.71 | 0.67 |
| 0.3    | 0.55    | 0.81 | 0.76 | 0.71 | 0.65 | 0.57 |
| 0.25   | 0.6     | 0.80 | 0.74 | 0.66 | 0.58 | 0.49 |
| 0.2    | 0.65    | 0.79 | 0.71 | 0.62 | 0.53 | 0.42 |
arteriovenous fistulas (AVFs),\textsuperscript{95–97} mainly mediated by increased infectious complications.\textsuperscript{98}

- Patients are yet to face increasing peritoneal membrane exposure to dialysis solutions, which eventually lead to changes in the peritoneal membrane with more fibrosis,\textsuperscript{99} decreased ultrafiltration capacity, poorer volume control,\textsuperscript{100} and possibly loss of nutrients due to rapid transport, thus increasing the mortality risk over time.\textsuperscript{101,102}

The point about CVCs is an important consideration. Perl et al. compared approximately 7400 PD patients, 6600 HD patients using AVFs or arteriovenous prosthetic bridge grafts (AVGs), and 24,000 HD patients using CVCs, all of whom started dialysis in 2001–2008. They found that the HD patients using AVFs had a similar or better survival compared to PD patients, whereas the CVC patients had 80% higher mortality than the PD patients. They explicitly conclude that “the use of CVCs in incident HD patients largely accounts for the early survival benefit seen with PD.”\textsuperscript{103} Another study from Portugal has supported this tenet,\textsuperscript{104} and a study from the United States Renal Data System 2010–2014.\textsuperscript{105} On the other hand, Kumar et al. compared 1003 matched patients, who started PD and HD in “optimal” fashion; in particular, the HD patients all started with permanent vascular access. The early survival benefit for PD was still evident in these “optimal” patients (see Figure 1), indicating that factors other than vascular access are still at play.\textsuperscript{5}

From these two studies, it is reasonable to conclude that vascular access is a very important determinant of the early survival benefit observed with PD, but not the only one. Perhaps more importantly, it is not conceivable that there will be a time that HD will be initiated only with arteriovenous access, just as it is not conceivable that PD will be undertaken without the occasional case of PD-related peritonitis. In the real world, with real-world patients and real-world practice settings, the observed survival benefit of PD relative to HD is likely to persist for the foreseeable future.

### Conclusions

Recently, a provocative editorial highlighted the focus of medical researchers with mortality risk on dialysis and the fact that they deprioritize of other important aspects of the patient experience.\textsuperscript{106} Notwithstanding, the answer to the question that the authors pose (“Survival by dialysis modality—who cares?”) is in fact “everyone.”\textsuperscript{107,108} Survival is among the top-ranked patient-centered outcomes, in addition to being a core clinical outcome. The authors of the provocative editorial are absolutely right of course—the spirit of their editorial is that patient-centered outcomes deserve more consideration by health-care professionals. However, the fact remains that survival on dialysis is still one of the most important considerations for all stakeholders in the ESKD community.

With this in mind, it behooves health-care professionals to tell patients they are likely to live a bit longer if they start their course on dialysis with PD, especially if they are to start HD with a CVC. Shared decision-making is a fundamental patient right and requires both balanced information and an iterative mechanism for a consensual decision based on shared understanding and values.\textsuperscript{109–111} It is known that
well-implemented predialysis education and/or shared decision-making results in patients prospectively choosing PD \( \sim 50\% \) of the time,\textsuperscript{112–118} which is similar to the reported preference of health-care professionals when they are presented with the hypothetical case of their own ESKD.\textsuperscript{119,120} There is an opportunity to improve patient satisfaction with the dialysis treatment through better shared decisions,\textsuperscript{121–130} with choices that better meet patient needs.\textsuperscript{131} A cornerstone of this process should be an explicit discussion of the early survival benefit of PD relative to HD.

**Acknowledgment**

The author would like to acknowledge the generous data sharing by Victoria A Kumar and Rajnish Mehrotra, the helpful comments from reviewers, and the insights and guidance of Edward F Vonesh over the years.

**Declaration of conflicting interests**

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The author is a paid employee of Counties Manukau District Health Board, University of Auckland, and Baxter Healthcare (Asia) Pte Ltd.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Mark R Marshall https://orcid.org/0000-0003-0499-4527

**Supplemental material**

Supplemental material for this article is available online.

**References**

1. Ross S, Dong E, Gordon M, et al. Meta-analysis of outcome studies in end-stage renal disease. *Kidney Int* 2000; 57: S28–S38.
2. Hernán MA. The hazards of hazard ratios. *Epidemiology* 2010; 21(1): 13–15.
3. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. *N Engl J Med* 2003; 349(6): 523–534.
4. Prentice RL, Pettinger M and Anderson GL. Statistical issues arising in the Women’s Health Initiative. *Biometrics* 2005; 61(4): 899–911; discussion 911–941.
5. Kumar VA, Sidell MA, Jones JP, et al. Survival of propensity matched incident peritoneal and hemodialysis patients in a United States health care system. *Kidney Int* 2014; 86(5): 1016–1022.
6. Vonesh E, Schaubel D, Hao W, et al. Statistical methods for comparing mortality among ESRD patients: examples of regional/international variations. *Kidney Int* 2000; 57(Suppl 74): S19–S27.
7. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. *Epidemiology* 2008; 19(6): 766–779.
8. Zhang Y, Thamer M, Cotter D, et al. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. *Clin J Am Soc Nephrol* 2009; 4(3): 638–644.
9. Yeates K, Zhu N, Vonesh E, et al. Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada. *Nephrol Dial Transplant* 2012; 27(9): 3568–3575.
10. Mehrotra R, Chiu YW, Kalantar-Zadeh K, et al. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. *Arch Intern Med* 2011; 171(2): 110–118.
11. Guyatt GH, Sackett DL, Sinclair JC, et al. Users’ guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. *JAMA* 1995; 274(22): 1800–1804.
12. Townsley CA, Selby R and Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. *J Clin Oncol* 2005; 23(13): 3112–3124.
13. Townsley CA, Chan KK, Pond GR, et al. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. *BMC Cancer* 2006; 6: 34.
14. Ridda I, MacIntyre CR, Lindley RI, et al. Difficulties in recruiting older people in clinical trials: an examination of barriers and solutions. *Vaccine* 2010; 28(4): 901–906.
15. Grande GE and Todd CJ. Why are trials in palliative care so difficult? *Palliat Med* 2000; 14(1): 69–74.
16. Witham MD and McMurdo ME. How to get older people included in clinical studies. *Drugs Aging* 2007; 24(3): 187–196.
17. Laegreid IK, Aasarod K and Jordhoy M. End-stage renal disease and recruitment to randomized trials: why is it so difficult? Results from a survey among Norwegian nephrologists. *Scand J Urol Nephrol* 2011; 45(4): 285–289.
18. Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial participation by older women with breast cancer. *J Clin Oncol* 2003; 21(12): 2268–2275.
19. Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. *N Engl J Med* 2012; 367(26): 2482–2494.
20. Arah OA, Chiba Y and Greenland S. Bias formulas for external adjustment and sensitivity analysis of unmeasured confounders. *Ann Epidemiol* 2008; 18(8): 637–646.
21. Fink AK, Fox MP and Lash TL. *Applying quantitative bias analysis to epidemiologic data*. New York: Springer-Verlag, 2009.
22. Sudan M, Kheifets L, Arah OA, et al. Cell phone exposures and hearing loss in children in the Danish National Birth Cohort. *Paediatr Perinat Epidemiol* 2013; 27(3): 247–257.
treatments, and confounders. *Epidemiology* 2011; 22(1): 42–52.

24. Lin DY, Psaty BM and Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. *Biometrics* 1998; 54(3): 948–963.

25. Goto A, Arah OA, Goto M, et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. *BMJ* 2013; 347: f5433.

26. Sudan M, Arah OA, Olsen J, et al. Reported associations between asthma and acute lymphoblastic leukemia: insights from a hybrid simulation study. *Eur J Epidemiol* 2016; 31(6): 593–602.

27. Amoon AT, Arah OA and Kheifets L. The sensitivity of reported effects of EMF on childhood leukemia to uncontrolled confounding by residential mobility: a hybrid simulation study and an empirical analysis using CAPS data. *Cancer Causes Control* 2019; 30(8): 901–908.

28. Marshall MR, Hsiao CY, Li PK, et al. Association of incident dialysis modality with mortality: a protocol for systematic review and meta-analysis of randomized controlled trials and cohort studies. *Syst Rev* 2019; 8(1): 55.

29. Koga S and Ito H. Mortality comparison of hemodialysis and peritoneal dialysis patients at a single Japanese center. *Adv Perit Dial* 2015; 31: 74–77.

30. Pike E, Hamidi V, Ringerike T, et al. More use of peritoneal dialysis gives significant savings: a systematic review and health economic decision model. *J Clin Med Res* 2017; 9(2): 104–116.

31. Ishani A, Slinin Y, Greer N, et al. *VA Evidence-based synthesis program reports. Comparative effectiveness of home-based kidney dialysis versus in-center or other outpatient kidney dialysis locations - a systematic review.* Washington, DC: Department of Veterans Affairs (US), 2015.

32. Sinclair A, Cimon K, Loncar M, et al. *CADTH optimal use reports. Dialysis modalities for the treatment of end-stage kidney disease: a health technology assessment.* Ottawa: Canadian Agency for Drugs and Technologies in Health, 2017.

33. Pike E, Hamidi V, Ringerike T, et al. *NIPH systematic reviews. health technology assessment of the different dialysis modalities in Norway.* Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH), 2013.

34. van de Luijtgaarden MW, Noordzij M, Stel VS, et al. Effects of comorbid and demographic factors on dialysis modality choice and related patient survival in Europe. *Nephrol Dial Transplant* 2011; 26(9): 2940–2947.

35. Heaf JG and Webberg S. Relative survival of peritoneal dialysis and haemodialysis patients: effect of cohort and mode of dialysis initiation. *PloS One* 2014; 9(3): e90119.

36. Plot Digitizer. http://plotdigitizer.sourceforge.net/ (2015, accessed 14 October 2019).

37. Vonesh EF, Snyder JJ, Foley RN, et al. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? *Kidney Int Suppl* 2006; (103): S3–S11.

38. Fenton SS, Schaubel DE, Desmeules M, et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. *Am J Kidney Dis* 1997; 30(3): 334–342.

39. Foley RN, Parfrey PS, Harnett JD, et al. Mode of dialysis therapy and mortality in end-stage renal disease. *J Am Soc Nephrol* 1998; 9(2): 267–276.

40. Schaubel DE, Morrison HI and Fenton SS. Comparing mortality rates on CAPD/CCPD and hemodialysis. The Canadian experience: fact or fiction? *Perit Dial Int* 1998; 18(5): 478–484.

41. Vonesh EF and Moran J. Mortality in end-stage renal disease: a reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. *J Am Soc Nephrol* 1999; 10(2): 354–365.

42. Collins AJ, Hao W, Xia H, et al. Mortality risks of peritoneal dialysis and hemodialysis. *Am J Kidney Dis* 1999; 34(6): 1065–1074.

43. Vigneau C, Trolliet P, Labeew M, et al. [Which method of dialysis for the type 2 diabetic?]. *Nephrologie* 2000; 21(4): 173–178.

44. Murphy SW, Foley RN, Barrett BJ, et al. Comparative mortality of hemodialysis and peritoneal dialysis in Canada. *Kidney Int* 2000; 57(4): 1720–1726.

45. Jager KJ, Merkus MP, Boeschoten EW, et al. What happens to patients starting dialysis in the Netherlands? *Neth J Med* 2001; 58(4): 163–173.

46. Heaf JG, Lokkengaard H and Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis.* Nephrol Dial Transplant* 2002; 17(1): 112–117.

47. Xue JL, Everson SE, Constantini EG, et al. Peritoneal and hemodialysis: II. Mortality risk associated with initial patient characteristics. *Kidney Int* 2002; 61(2): 741–746.

48. Termorshuizen F, Korevaar JC, Dekker FW, et al. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis 2. *J Am Soc Nephrol* 2003; 14(11): 2851–2860.

49. Ganesh SK, Hulbert-Shearon T, Port FK, et al. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. *J Am Soc Nephrol* 2003; 14(2): 415–424.

50. Vonesh EF, Snyder JJ, Foley RN, et al. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. *Kidney Int* 2004; 66(6): 2389–2401.

51. Jaar BG, Coresh J, Plantinga LC, et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. *Ann Intern Med* 2005; 143(3): 174–183.

52. Huang CC, Cheng KF and Wu HD. Survival analysis: comparing peritoneal dialysis and hemodialysis in Taiwan. *Perit Dial Int* 2008; 28 Suppl 3: S15–S20.

53. Liem YS, Wong JB, Hunink MG, et al. Comparison of hemodialysis and peritoneal dialysis survival in the Netherlands. *Kidney Int* 2007; 71(2): 153–158.

54. Andrikos E, Tseke P, Balafa O, et al. Five-year survival in comparable HD and PD patients: one center’s experience. *Int J Artif Organs* 2008; 31(8): 737–741.

55. Lee EJ. Risk stratification of the peritoneal dialysis patient-a single-center experience. *Perit Dial Int* 2008; 28 Suppl 3: S32–S35.
56. Sanabria M, Munoz J, Trillos C, et al. Dialysis outcomes in Colombia (DOC) study: a comparison of patient survival on peritoneal dialysis vs hemodialysis in Colombia. *Kidney Int Suppl* 2008; (108): S165–S172.

57. Ganeshadeva YM, Goh BL, Chew SE, et al. A single-center audit of complication rates between hemodialysis and peritoneal dialysis patients. *Hemodialysis Int* 2009; 13(3): 388–389.

58. Lee CC, Sun CY and Wu MS. Long-term modality-related mortality analysis in incident dialysis patients. *Perit Dial Int* 2009; 29(2): 182–190.

59. McDonald SP, Marshall MR, Johnson DW, et al. Relationship between dialysis modality and mortality. *J Am Soc Nephrol* 2009; 20(1): 155–163.

60. Weinhandl ED, Foley RN, Gilbertson DT, et al. Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. *J Am Soc Nephrol* 2010; 21(3): 499–506.

61. Quinn RR, Hux JE, Oliver MJ, et al. Selection bias explains apparent differential mortality between dialysis modalities. *J Am Soc Nephrol* 2011; 22(8): 1534–1542.

62. Wu B, Wang M, Gan L, et al. Comparison of patient survival between hemodialysis and peritoneal dialysis in a single Chinese center. *Int Urol Nephrol* 2014; 46(12): 2403–2407.

63. Hou F, Jiang J, Chen J, et al. China collaborative study on dialysis: a multi-centers cohort study on cardiovascular diseases in patients on maintenance dialysis. *Nefrologı́a* 2012; 13: 94.

64. Rufino JM, Garcia C, Vega N, et al. Current peritoneal dialysis compared with haemodialysis: medium-term survival analysis of incident dialysis patients in the Canary Islands in recent years. *Nefrologı́a* 2011; 31(2): 174–184.

65. Chang YK, Hsu CC, Hwang SJ, et al. A comparative assessment of survival between propensity score-matched patients with peritoneal dialysis and hemodialysis in Taiwan. *Medicine (Baltimore)* 2012; 91(3): 144–151.

66. Suzuki K, Konta T, Ichikawa K, et al. Comparison of mortality between Japanese peritoneal dialysis and hemodialysis patients: a 5-year multicenter follow-up study. *Int J Nephrol* 2012; 2012: 231018.

67. Haapio M, Helve J, Kyllonen L, et al. Modality of chronic renal replacement therapy and survival-a complete cohort from Finland, 2000-2009. *Nephrol Dial Transplant* 2013; 28(12): 3072–3081.

68. Chang JH, Sung JY, Ahn SY, et al. Hemodialysis leads to better survival in patients with diabetes or high comorbidity, compared to peritoneal dialysis. *Tohoku J Exp Med* 2013; 229(4): 271–277.

69. Lukowsky LR, Mehrotra R, Kheifets L, et al. Comparing mortality of peritoneal and hemodialysis patients in the first 2 years of dialysis therapy: a marginal structural model analysis. *Clin J Am Soc Nephrol* 2013; 8(4): 619–628.

70. Choi JY, Jang HM, Park J, et al. Survival advantage of peritoneal dialysis relative to hemodialysis in the early period of incident dialysis patients: a nationwide prospective propensity-matched study in Korea. *PLoS One* 2013; 8(12): e84257.

71. Kim H, Kim KH, Park K, et al. A population-based approach indicates an overall higher patient mortality with peritoneal dialysis compared to hemodialysis in Korea. *Kidney Int* 2014; 86(5): 991–1000.

72. Kramer A, Pippias M, Noordzij M, et al. The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry annual report 2015: a summary. *Clin Kidney J* 2018; 11(1): 108–122.

73. Wang IK, Lin CL, Yen TH, et al. Comparison of survival between hemodialysis and peritoneal dialysis patients with end-stage renal disease in the era of icodextrin treatment. *Eur J Intern Med* 2018; 50: 69–74.

74. Yang JY, Chen L, Chao CT, et al. Comparative study of outcomes among patients with polycystic kidney disease on hemodialysis and peritoneal dialysis. *Sci Rep* 2015; 5: 12816.

75. Mircescu G, Stefan G, Garneata L, et al. Outcomes of dialytic modalities in a large incident registry cohort from Eastern Europe: the Romanian Renal Registry. *Int Urol Nephrol* 2014; 46(2): 443–451.

76. Refaat H, Sany D, Mohab A, et al. Comparing dialysis modality and cardiovascular mortality in patients on hemodialysis and peritoneal dialysis. *Adv Perit Dial* 2016; 32: 22–31.

77. Higgins J and Deeks J (eds) Chapter 7.7.3.2. Obtaining standard deviations from standard errors and confidence intervals for group means. In: Higgins JPT and Green S (eds) *Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011)*. London: The Cochrane Collaboration, 2011.

78. DerSimonian R and Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; 7(3): 177–188.

79. Marshall MR, Walker RC, Polkinghome KR, et al. Survival on home dialysis in New Zealand. *PLoS One* 2014; 9(5): e96847.

80. Marshall MR, Hawley CM, Kerr PG, et al. Home hemodialysis and mortality risk in Australian and New Zealand populations. *Am J Kidney Dis* 2011; 58(5): 782–793.

81. Gutman RA, Blumenkrantz MJ, Chan YK, et al. Controlled comparison of hemodialysis and peritoneal dialysis: Veterans Administration multicenter study. *Kidney Int* 1984; 26(4): 459–470.

82. Yu X, Fan L, Marshall MR, et al. Primary results of the quality of life in peritoneal dialysis and conventional in-center hemodialysis (China Q) study: a prospective, randomized, open-label, multicenter, non-inferiority trial. *J Am Soc Nephrol* 2018; 29: B4.

83. Korevaar JC, Feith GW, Dekker FW, et al. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. *Kidney Int* 2003; 64(6): 2222–2228.

84. Vale L, Cody J, Wallace S, et al. Continuous ambulatory peritoneal dialysis (CAPD) versus hospital or home haemodialysis for end-stage renal disease in adults. *Cochrane Database Syst Rev* 2004; (4): Cd003963.
85. Greenland S. Useful methods for sensitivity analysis of observational studies. *Biometrics* 1999; 55(3): 990–991.
86. Bargman JM, Thorpe KE and Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. *J Am Soc Nephrol* 2001; 12(10): 2158–2162.
87. Shemin D, Bostom AG, Laliberty P, et al. Residual renal function and mortality risk in hemodialysis patients. *Am J Kidney Dis* 2001; 38(1): 85–90.
88. Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. *J Am Soc Nephrol* 2000; 11(3): 556–564.
89. Wang AY, Wang M, Woo J, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. *J Am Soc Nephrol* 2004; 15(8): 2186–2194.
90. Canadian Institute for Health Information. CORR annual statistics, 2017: renal replacement therapy for end-stage kidney disease, 1996 to 2015, https://www.cihi.ca/en/access-data-and-search+Submit (2017, accessed 14 October 2019).
91. Noordzij M, Jager KJ, van der Veer SN, et al. Use of vascular access for haemodialysis in Europe: a report from the ERA-EDTA Registry. *Nephrol Dial Transplant* 2014; 29(10): 1956–1964.
92. ANZDATA. ANZDATA registry 40th report, chapter 4: haemodialysis. Adelaide, Australia: Australia and New Zealand Dialysis and Transplant Registry, 2018, http://www.anzdata.org.au (2018, accessed 14 October 2019).
93. Saran R, Robinson B, Abbott KC, et al. US renal data system 2018 annual data report: epidemiology of kidney disease in the United States. *Am J Kidney Dis* 2019; 73(S31): A7–A8.
94. United States Renal Data System. 2018 USRDS annual data report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2018.
95. Polkinghorne KR, McDonald SP, Atkins RC, et al. Vascular access and all-cause mortality: a propensity score analysis. *J Am Soc Nephrol* 2004; 15(2): 477–486.
96. Dhingra RK, Young EW, Hulbert-Shearon TE, et al. Type of vascular access and mortality in U.S. hemodialysis patients. *Kidney Int* 2001; 60(4): 1443–1451.
97. Almasri J, Alsawas M, Mainou M, et al. Outcomes of vascular access for hemodialysis: a systematic review and meta-analysis. *J Vasc Surg* 2016; 64(1): 236–243.
98. Ravani P, Quinn R, Oliver M, et al. Examining the association between hemodialysis access type and mortality: the role of access complications. *Clin J Am Soc Nephrol* 2017; 12(6): 955–964.
99. Davies SJ, Phillips L, Naish PF, et al. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. *J Am Soc Nephrol* 2001; 12(5): 1046–1051.
100. Krediet RT, Van Esch S, Smit W, et al. Peritoneal membrane failure in peritoneal dialysis patients. *Blood Purif* 2002; 20(5): 489–493.
101. Churchill DN, Thorpe KE, Nolph KD, et al. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. *J Am Soc Nephrol* 1998; 9(7): 1285–1292.
102. Perl J and Bargman JM. The importance of residual kidney function for patients on dialysis: a critical review. *Am J Kidney Dis* 2009; 53(6): 1068–1081.
103. Perl J, Wald R, McFarlane P, et al. Hemodialysis vascular access modifies the association between dialysis modality and survival. *J Am Soc Nephrol* 2011; 22(6): 1113–1121.
104. Coentrao L, Santos-Araujo C, Dias C, et al. Effects of starting hemodialysis with an arteriovenous fistula or central venous catheter compared with peritoneal dialysis: a retrospective cohort study. *BMC Nephrol* 2012; 13: 88.
105. Mukhopadhyay P, Woodside KJ, McCullough K, et al. First-year mortality among patients initiating hemodialysis with a functional arteriovenous fistula compared with peritoneal dialysis. *J Am Soc Nephrol* 2017; 28: 637.
106. Lee MB and Bargman JM. Survival by dialysis modality—who cares? *Clin J Am Soc Nephrol* 2016; 11(6): 1083–1087.
107. Evangelidis N, Tong A, Manns B, et al. Developing a set of core outcomes for trials in hemodialysis: an International Delphi Survey. *Am J Kidney Dis* 2017; 70(4): 464–475.
108. Manera KE, Tong A, Craig JC, et al. An International Delphi survey helped develop consensus-based core outcome domains for trials in peritoneal dialysis. *Kidney Int* 2019; 96(3): 699–710.
109. Coulter A. Do patients want a choice and does it work? *BMJ* 2010; 341: c4989.
110. Moulton B, Collins PA, Burns-Cox N, et al. From informed consent to informed request: do we need a new gold standard? *J R Soc Med* 2013; 106(10): 391–394.
111. Coulter A. Court judgment on consent provides spur for embracing shared decision making. *BMJ* 2015; 350: h3482.
112. Manns BJ, Taub K, Vanderstraeten C, et al. The impact of education on chronic kidney disease patients’ plans to initiate dialysis with self-care dialysis: a randomized trial. *Kidney Int* 2005; 68(4): 1777–1783.
113. Little J, Irwin A, Marshall T, et al. Predicting a patient’s choice of dialysis modality: experience in a United Kingdom renal department. *Am J Kidney Dis* 2001; 37(5): 981–986.
114. Ahlmen J, Carlsson L and Schonborg C. Well-informed patients with end-stage renal disease prefer peritoneal dialysis to hemodialysis. *Perit Dial Int* 1993; 13 Suppl 2: S196–S198.
115. Prichard SS. Treatment modality selection in 150 consecutive patients starting ESRD therapy. *Perit Dial Int* 1996; 16(1): 69–72.
116. Marron B, Martinez Ocana JC, Salgueira M, et al. Analysis of patient flow into dialysis: role of education in choice of dialysis modality. *Perit Dial Int* 2005; 25 Suppl 3: S56–S59.
117. Ribitsch W, Haditsch B, Otto R, et al. Effects of a pre-dialysis patient education program on the relative frequencies of dialysis modalities. *Perit Dial Int* 2013; 33(4): 367–371.

118. Devoe DJ, Wong B, James MT, et al. Patient education and peritoneal dialysis modality selection: a systematic review and meta-analysis. *Am J Kidney Dis* 2016; 68(3): 422–433.

119. Schiller B, Neitzer A and Doss S. Perceptions about renal replacement therapy among nephrology professionals. *Nephrol News Issues* 2010; 24(10): 36,38,40 passim.

120. Merighi JR, Schatell DR, Bragg-Gresham JL, et al. Insights into nephrologist training, clinical practice, and dialysis choice. *Hemodial Int* 2012; 16(2): 242–251.

121. Ladin K, Lin N, Hahn E, et al. Engagement in decision-making and patient satisfaction: a qualitative study of older patients’ perceptions of dialysis initiation and modality decisions. *Nephrol Dial Transplant* 2017; 32(8): 1394–1401.

122. Rubin HR, Fink NE, Plantinga LC, et al. Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis. *JAMA* 2004; 291(6): 697–703.

123. Wasserfallen JB, Moinat M, Halabi G, et al. Satisfaction of patients on chronic haemodialysis and peritoneal dialysis. *Swiss Med Wkly* 2006; 136(13–14): 210–217.

124. Juergensen E, Wuerth D, Finkelstein SH, et al. Hemodialysis and peritoneal dialysis: patients’ assessment of their satisfaction with therapy and the impact of the therapy on their lives. *Clin J Am Soc Nephrol* 2006; 1(6): 1191–1196.

125. McLaughlin K, Manns B, Mortis G, et al. Why patients with ESRD do not select self-care dialysis as a treatment option. *Am J Kidney Dis* 2003; 41(2): 380–385.

126. Finkelstein AF, Wuerth D and Finkelstein SH. Quality of life assessments in hemodialysis and peritoneal dialysis patients: an important dimension of patient choice why is the evidence favoring hemodialysis over peritoneal dialysis misleading? *Semin Dial* 2007; 20(3): 211–213.

127. Goodlad C and Brown E. The role of peritoneal dialysis in modern renal replacement therapy. *Postgrad Med J* 2013; 89(1056): 584–590.

128. de Abreu MM, Walker DR, Sesso RC, et al. Health-related quality of life of patients receiving hemodialysis and peritoneal dialysis in Sao Paulo, Brazil: a longitudinal study. *Value Health* 2011; 14(Suppl 1): S119–S121.

129. Fadem SZ, Walker DR, Abbott G, et al. Satisfaction with renal replacement therapy and education: the American Association of Kidney Patients survey. *Clin J Am Soc Nephrol* 2011; 6(3): 605–612.

130. Molsted S, Prescott L, Heaf J, et al. Assessment and clinical aspects of health-related quality of life in dialysis patients and patients with chronic kidney disease. *Nephron Clin Pract* 2007; 106(1): c24–c33.

131. Robinski M, Mau W, Wiencek A, et al. Shared decision-making in chronic kidney disease: a retrospective of recently initiated dialysis patients in Germany. *Patient Educ Couns* 2016; 99(4): 562–570.